<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drugs</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>WHO declares Ebola outbreak a public health emergency of international concern</title>
      <description>
        <![CDATA[The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of the virus, for which there are no approved vaccines or antiviral therapies. At the same time, the high positivity rate, with eight laboratory confirmed cases out of 13 samples collected in various areas, and more reports of suspected cases and clusters of deaths, all point to a potentially much larger outbreak than currently is being detected and reported.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731367</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731367-who-declares-ebola-outbreak-a-public-health-emergency-of-international-concern</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Microscopic-view-of-ebola-virus.webp?t=1779114011" type="image/jpeg" medium="image" fileSize="124502">
        <media:title type="plain">Microscopic view of the ebola virus</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731364</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731364-daewoong-nabs-innovos-preclinical-ibd-asset-in-663b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Daewoong-Innovo-CEOs-5-13.webp?t=1778686979" type="image/jpeg" medium="image" fileSize="116766">
        <media:title type="plain">Daewong CEO Park Sung-soo (left) with Innovo CEO Park Hee-dong</media:title>
        <media:description type="plain">Daewong Pharmaceutical CEO Park Sung-soo (left) with Innovo Therapeutics CEO Park Hee-dong.</media:description>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731362</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731362-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>CDC vaccines panel to be ‘re-established’</title>
      <description>
        <![CDATA[It’s back to the drawing board for the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP). After a year of Health and Human Services Secretary Robert Kennedy gutting the panel and restocking it mostly with people who share his views on vaccines, the CDC published a notice in the May 19 <em>Federal Register</em> saying it’s withdrawing the amended ACIP charter renewal issued April 6 and is instead “re-establishing” the committee.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731331</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731331-cdc-vaccines-panel-to-be-re-established</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Three-syringes-illustration.webp?t=1779225653" type="image/jpeg" medium="image" fileSize="270206">
        <media:title type="plain">Three syringes illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Vincentage’s oral GLP-1 meets phase III obesity endpoints   </title>
      <description>
        <![CDATA[Vincentage Pharma Co. Ltd.’s once-daily oral small-molecule GLP-1 receptor agonist, VCT-220, met the primary endpoints in a pivotal phase III trial in overweight or obese patients in China. Based on the top-line data, the Chengdu, China-based company plans to submit an NDA for chronic weight management to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731330</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731330-vincentages-oral-glp-1-meets-phase-iii-obesity-endpoints</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Oral-medication.webp?t=1652383335" type="image/png" medium="image" fileSize="350602">
        <media:title type="plain">Oral medication</media:title>
      </media:content>
    </item>
    <item>
      <title>Relay’s zovegalisib hits in phase II vascular anomalies trial</title>
      <description>
        <![CDATA[Showing a significant efficacy signal in a phase II trial, Relay Therapeutics Inc.’s zovegalisib (RLY-2608) achieved a 60% volumetric response in patients with PIK3CA-driven vascular anomalies (VAs). The isoform-selective PI3Ka inhibitor is in late-stage clinical trials with various combinations for P13Ka-mutated, HR+/HER2- advanced breast cancer, with VAs representing a second indication for which Leerink Partners analyst Andrew Berens forecasts $2.8 billion in peak revenues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731325</guid>
      <pubDate>Tue, 19 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731325-relays-zovegalisib-hits-in-phase-ii-vascular-anomalies-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-vessels-veins-and-arteries.webp?t=1771963864" type="image/jpeg" medium="image" fileSize="111333">
        <media:title type="plain">Blood vessels, veins and arteries</media:title>
      </media:content>
    </item>
    <item>
      <title>Bundibugyo is harsh reminder of need for broad vaccine strategies</title>
      <description>
        <![CDATA[On Sunday, May 17th, 2026, the World Health Organization classified the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo (DRC) as a public health emergency of international concern (PHEIC). The rapid escalation to PHEIC is due to several factors. Given the high number of cases, the outbreak has likely been going undetected for some time, and may be a “much larger outbreak than what is currently being detected and reported, with significant local and regional risk of spread,” according to the WHO statement. The outbreak appears to already have crossed the border from the DRC into Uganda at least twice. And all this is happening with a virus for which there are no approved treatments or vaccines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731356</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731356-bundibugyo-is-harsh-reminder-of-need-for-broad-vaccine-strategies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-vaccine-illustration.webp?t=1779130335" type="image/png" medium="image" fileSize="345545">
        <media:title type="plain">Virus and vaccine illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Iksuda and UCL report new B7-H3-targeting ADCs</title>
      <description>
        <![CDATA[Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for potential use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731168</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731168-iksuda-and-ucl-report-new-b7-h3-targeting-adcs</link>
    </item>
    <item>
      <title>Dual-payload ADC holds promise for treating HER2+ tumors </title>
      <description>
        <![CDATA[Antibody-drug conjugates (ADCs) with a dual payload, which deliver two distinct cytotoxic agents via a single antibody, are emerging therapeutics developed to address the limitations of classic ADCs. Primelink Biotherapeutics (Shenzhen) Co. Ltd. recently presented data for their dual-payload ADCs, highlighting PLB-015, which carries a TOP1 inhibitor and an ATR inhibitor with an anti-HER2 antibody and is designed to inhibit the DNA damage response activated by cancer cells when harmed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731163</guid>
      <pubDate>Tue, 19 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731163-dual-payload-adc-holds-promise-for-treating-her2-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/ADC-illustration.webp?t=1763043550" type="image/jpeg" medium="image" fileSize="320648">
        <media:title type="plain">Antibody-drug conjugates floating on light purple background</media:title>
      </media:content>
    </item>
    <item>
      <title>Bundibugyo is harsh reminder of need for broad vaccine strategies</title>
      <description>
        <![CDATA[On Sunday, May 17th, 2026, the World Health Organization classified the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo (DRC) as a public health emergency of international concern (PHEIC). The rapid escalation to PHEIC is due to several factors. Given the high number of cases, the outbreak has likely been going undetected for some time, and may be a “much larger outbreak than what is currently being detected and reported, with significant local and regional risk of spread,” according to the WHO statement. The outbreak appears to already have crossed the border from the DRC into Uganda at least twice. And all this is happening with a virus for which there are no approved treatments or vaccines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731311</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731311-bundibugyo-is-harsh-reminder-of-need-for-broad-vaccine-strategies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-vaccine-illustration.webp?t=1779130335" type="image/png" medium="image" fileSize="345545">
        <media:title type="plain">Virus and vaccine illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>New hypertension option as Astrazeneca’s Baxfendy wins FDA nod</title>
      <description>
        <![CDATA[Patients on antihypertensive medications who still struggle with high blood pressure now have a new treatment option, following the U.S. FDA’s approval of Astrazeneca plc’s baxdrostat. Branded Baxfendy, the drug is a first-in-class aldosterone synthase inhibitor, though it could be joined soon by potential competitor Mineralys Therapeutics Inc., which has a December 2026 PDUFA date for its aldosterone synthase inhibitor, lorundrostat.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731309</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731309-new-hypertension-option-as-astrazenecas-baxfendy-wins-fda-nod</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Blood-pressure-cuff.webp?t=1709666702" type="image/png" medium="image" fileSize="439332">
        <media:title type="plain">Blood pressure cuff </media:title>
      </media:content>
    </item>
    <item>
      <title>Authorities work to quickly sequence Ebola species in latest outbreak</title>
      <description>
        <![CDATA[If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the Democratic Republic of the Congo. While sequencing is ongoing to identify the Ebola species, experts have noted early results suggesting it appears to be different from the Zaire species that has caused previous outbreaks, including the deadliest outbreak in West Africa a decade ago, meaning existing vaccines and antibody treatments likely will not be effective.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731208</guid>
      <pubDate>Mon, 18 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731208-authorities-work-to-quickly-sequence-ebola-strain-in-latest-outbreak</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Ebola-virus-particle.webp?t=1778876547" type="image/jpeg" medium="image" fileSize="129839">
        <media:title type="plain">Ebola virus particle</media:title>
        <media:description type="plain">Scanning electron micrograph of a single filamentous Ebola virus particle. Credit: U.S. NIAID
</media:description>
      </media:content>
    </item>
    <item>
      <title>IND-enabling studies of adult RPE stem cell product for dry AMD</title>
      <description>
        <![CDATA[Cell replacement therapy is currently being investigated to restore the retinal pigment epithelium (RPE) layer and treat vision decline due to dry age-related macular degeneration (AMD). The Neural Stem Cell Institute and collaborating institutions developed an approach to RPE replacement using an adult RPE stem cell source derived from the RPE layer of donated cadaver eyes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731142</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731142-ind-enabling-studies-of-adult-rpe-stem-cell-product-for-dry-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Senior-eye-exam.webp?t=1686607556" type="image/jpeg" medium="image" fileSize="176885">
        <media:title type="plain">Senior eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>MD Anderson gains IND nod for CD94-targeted CAR T therapy </title>
      <description>
        <![CDATA[The University of Texas MD Anderson Cancer Center has received IND clearance from the FDA to initiate a phase I trial of a novel CAR T-cell therapy, JV-394, for patients with relapsed or refractory CD94-positive T/natural killer (NK) cell lymphomas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731141</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731141-md-anderson-gains-ind-nod-for-cd94-targeted-car-t-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/CAR-T-cell-attacking-a-cancer-cell.webp?t=1759242499" type="image/jpeg" medium="image" fileSize="874683">
        <media:title type="plain">Computer visualization of a CAR T cell attacking a cancer cell.</media:title>
        <media:description type="plain">Computer visualization of a CAR T cell attacking a cancer cell. Credit: C. Bock, CeMM.</media:description>
      </media:content>
    </item>
    <item>
      <title>GPX-002 restores β-cell function in a diabetes model </title>
      <description>
        <![CDATA[Type 2 diabetes is marked by insulin resistance coupled with insufficient insulin secretion due to early β-cell dysfunction and progressive loss of β-cell mass. Pdx1 and MafA, critical for maintaining β-cell function, are progressively reduced under metabolic stress and in patients, driving disease progression. Researchers at the University of Pittsburgh have reported efficacy data demonstrating successful pancreatic delivery of GPX-002, an AAV-Pdx1/MafA construct, in HFD mice.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731140</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731140-gpx-002-restores-cell-function-in-a-diabetes-model</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-metabolic-pancreas-anatomy-illustration.webp?t=1774020868" type="image/jpeg" medium="image" fileSize="655771">
        <media:title type="plain">Pancreas anatomy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Harbour Biomed’s LET-003 shows promise for obesity</title>
      <description>
        <![CDATA[Harbour Biomed has released preclinical data for LET-003, a next-generation ACVR2A/2B-targeted monoclonal antibody with potential for the treatment of obesity. Activin receptors ACVR2A and ACVR2B play critical roles in regulating muscle-fat metabolic homeostasis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731139</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731139-harbour-biomeds-let-003-shows-promise-for-obesity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Monoclonal-antibody-therapy.webp?t=1731516507" type="image/jpeg" medium="image" fileSize="136228">
        <media:title type="plain">Illustration of monoclonal antibody hovering between doctor's hands</media:title>
      </media:content>
    </item>
    <item>
      <title>AAV-encoded dimeric PICK1 inhibitors reduce inflammatory, neuropathic pain in mice</title>
      <description>
        <![CDATA[Researchers from the University of Copenhagen and collaborating institutions aimed to develop a therapy for chronic neuropathic pain based on gene therapy delivered with adeno-associated viral (AAV) vectors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731138</guid>
      <pubDate>Mon, 18 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731138-aav-encoded-dimeric-pick1-inhibitors-reduce-inflammatory-neuropathic-pain-in-mice</link>
    </item>
    <item>
      <title>WHO declares Ebola outbreak a public health emergency of international concern</title>
      <description>
        <![CDATA[The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of the virus, for which there are no approved vaccines or antiviral therapies. At the same time, the high positivity rate, with eight laboratory confirmed cases out of 13 samples collected in various areas, and more reports of suspected cases and clusters of deaths, all point to a potentially much larger outbreak than currently is being detected and reported.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731355</guid>
      <pubDate>Mon, 18 May 2026 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731355-who-declares-ebola-outbreak-a-public-health-emergency-of-international-concern</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Microscopic-view-of-ebola-virus.webp?t=1779114011" type="image/jpeg" medium="image" fileSize="124502">
        <media:title type="plain">Microscopic view of the ebola virus</media:title>
      </media:content>
    </item>
    <item>
      <title>Validity of Actelion patent hinges on temperature </title>
      <description>
        <![CDATA[Temperature matters when determining pH levels. Whether that level should be measured at a standard room temperature or refrigerated matters even more, at least in Actelion Ltd.’s infringement litigation against Mylan Inc. According to Johnson & Johnson’s Actelion, the pH level in epoprostenol, the key ingredient in its hypertension drug Veletri, should be measured at a refrigerated temperature when it comes to Mylan’s generic formulation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731211</guid>
      <pubDate>Fri, 15 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731211-validity-of-actelion-patent-hinges-on-temperature</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/pH-testing.webp?t=1778865955" type="image/jpeg" medium="image" fileSize="74585">
        <media:title type="plain">Test tube and pH chart</media:title>
      </media:content>
    </item>
    <item>
      <title>Antelope Therapeutics patents new antibody-drug conjugates for cancer</title>
      <description>
        <![CDATA[A recent Antelope Therapeutics SAS patent describes new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting canAg (CA242) mucin glycoepitope covalently linked to exatecan designed for use in the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731133</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731133-antelope-therapeutics-patents-new-antibody-drug-conjugates-for-cancer</link>
    </item>
    <item>
      <title>CSPC Megalith Biopharmaceutical  discloses new CDCP1-targeting ADCs</title>
      <description>
        <![CDATA[CSPC Megalith Biopharmaceutical Co. Ltd. has discovered new antibody-drug conjugates (ADCs) consisting of antibodies targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731132</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731132-cspc-megalith-biopharmaceutical-discloses-new-cdcp1-targeting-adcs</link>
    </item>
    <item>
      <title>Launch of CGTxchange to reactivate cell and gene therapy programs</title>
      <description>
        <![CDATA[The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have announced the public launch of CGTxchange, an AI-enhanced clearinghouse and marketplace built to help reactivate cell and gene therapy programs that have been shelved despite strong scientific and clinical evidence.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731124</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731124-launch-of-cgtxchange-to-reactivate-cell-and-gene-therapy-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Archive-room.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="314054">
        <media:title type="plain">Dimly lit archive room filled with cardboard storage boxes</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Create Medicines to advance in vivo CAR therapies</title>
      <description>
        <![CDATA[Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform directly engineers T cells, NK cells and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731122</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731122-financing-at-create-medicines-to-advance-in-vivo-car-therapies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/dollar-sign-dropper.webp?t=1593437965" type="image/png" medium="image" fileSize="1167950">
        <media:title type="plain">Dollar sign dropper and test tube</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Directed evolution in gene therapy</title>
      <description>
        <![CDATA[Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and delivery vectors. Molecular diversification methods are increasingly sophisticated and are now accelerated by machine learning and AI tools, as showcased at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Boston this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731119</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-and-genome-editing.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="96216">
        <media:title type="plain">DNA and genome editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>USPTO doubles down on inconsistencies in dual IPR-court action</title>
      <description>
        <![CDATA[The U.S. Patent and Trademark Office (USPTO) is driving home its message that inter partes reviews (IPRs) are not to be used in conjunction with court action presenting “inconsistent positions” as a litigation strategy. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731197</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731197-uspto-doubles-down-on-inconsistencies-in-dual-ipr-court-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Patent-wheels.webp?t=1588870185" type="image/png" medium="image" fileSize="648858">
        <media:title type="plain">Patent gears</media:title>
      </media:content>
    </item>
    <item>
      <title>Will FDA show Affinity for fast yes to Regenxbio in DMD?</title>
      <description>
        <![CDATA[How the U.S. FDA might view the latest Duchenne muscular dystrophy (DMD) phase III data with gene therapy RGX-202 became the question for Regenxbio Inc., shares of which &nbsp;(NASDAQ:RGNX) closed May 14 at $6.25, down 38%, or $3.80, after the results were made public.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731196</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731196-will-fda-show-affinity-for-fast-yes-to-regenxbio-in-dmd</link>
      <media:content url="https://www.bioworld.com/ext/resources/2023/06/02/Green-arrow-up-red-arrow-down.webp?t=1685735888" type="image/jpeg" medium="image" fileSize="43614">
        <media:title type="plain">Green arrow up red arrow down</media:title>
      </media:content>
    </item>
    <item>
      <title>Biogen AD drug shows tau, cognition benefit, despite trial miss </title>
      <description>
        <![CDATA[Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide therapy, originally discovered by Ionis Pharmaceuticals Inc., missed its phase II primary endpoint.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731195</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731195-biogen-ad-drug-shows-tau-cognition-benefit-despite-trial-miss</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIA-Alzheimers-Abnormal-Tau.webp?t=1672942298" type="image/png" medium="image" fileSize="2087052">
        <media:title type="plain">Illustration of tau accumulating in a neuron cell.</media:title>
      </media:content>
    </item>
    <item>
      <title>Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal </title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license agreement has potential to tally $4.7 billion for Aribio, marking the largest deal for an AD asset inked by a Korean biotech company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731194</guid>
      <pubDate>Thu, 14 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731194-fosun-secures-rights-to-aribios-ar-1001-in-potential-47b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>KHN-921 gains IND clearance for &lt;em&gt;MYBPC3&lt;/em&gt;-associated HCM</title>
      <description>
        <![CDATA[Chengdu Origen Biotechnology Co. Ltd. and Vanotech Ltd. have announced IND clearance by the FDA for KHN-921 for the treatment of hypertrophic cardiomyopathy (HCM) associated with <em>MYBPC3</em> mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731095</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731095-khn-921-gains-ind-clearance-for-emmybpc3-em-associated-hcm</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Abstract-blue-human-heart-with-red-cardio-pulse-line-and-red-circle.webp?t=1752266610" type="image/png" medium="image" fileSize="259569">
        <media:title type="plain">Abstract blue human heart with red cardio pulse line and red circle</media:title>
      </media:content>
    </item>
    <item>
      <title>Henlius’ HLX-48 for solid tumors cleared for clinic in Australia</title>
      <description>
        <![CDATA[Shanghai Henlius Biotech Inc.’s HLX-48 for injection has received approval from the Human Research Ethics Committee (HREC) in Australia and been acknowledged by the Therapeutic Goods Administration (TGA). The first-in-human phase I study in Australia will evaluate HLX-48 in patients with advanced or metastatic solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731092</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731092-henlius-hlx-48-for-solid-tumors-cleared-for-clinic-in-australia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-tumor-blood-vessels.webp?t=1691420296" type="image/jpeg" medium="image" fileSize="242637">
        <media:title type="plain">3D illustration of tumor</media:title>
      </media:content>
    </item>
  </channel>
</rss>
